Nyxoah Announces Submission of Draft Registration Statement for Proposed Public Listing in the United States
Mont-Saint-Guibert, Belgium – 19 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F-1 to the Securities and Exchange Commission (the 'SEC') relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.
This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the 'Securities Act').
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the Securities Act.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).
-
Most popular related searches
Related products
Genio - Obstructive Sleep Apnea System (OSA)
Related news
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, Israel and Basel, Switzerland, 12 August 2021 – Sheba Medical Center at Tel Hashomer, the largest hospital in the...
-
Flat Medical announced FDA 510(k) clearance of EpiFaith, the Epidural Safety Solution
Flat Medical Co., Ltd., the medtech company specializing in clinical safety solutions, announced it received 510(k) clearance from the U.S. Food and Drug Administration for its EpiFaith® syringe to deliver safe epidural locating solution. Based on the LOR technique, the EpiFaith® syringe is a physician-centered safeguard for epidural analgesia, which is indicated for painless labor, surgical anesthesia and chronic pain management. Compared with traditional practice that relies on the manual sense, EpiFaith&...
-
Koning Goes Live on Investment Platform, Revere
Koning Corporation is now live on the investment platform, Revere, which specializes in raising funds for scalable, high-value technology companies. “We’re excited to bring this opportunity to investors who believe, like we do, in the advancement of women’s health through better breast imaging techniques,” says Koning’s US CEO, Lutao Ning. “We believe that our technology has the potential to significantly lower breast cancer incidents in women around the world.” Breast...
-
Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies
Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases. Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene. INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration...
-
The Chinese University of Hong Kong and Aurora Medical Technology Hong Kong to collaborate on breast cancer research program
Aurora Medical Technology Hong Kong (Aurora-HK) and The Chinese University of Hong Kong (CUHK) are pleased to announce the completion of a landmark collaboration agreement leveraging the shared interests and diverse expertise of the two entities.Led by Winnie chiu-wing Chu MD, Professor of radiology at CUHK and Abraham Morse MD, Medical Director of Aurora, the joint project will investigate the potential advantages and challenges of using breast-dedicated MRI for first-line breast cancer screening in Chinese...
Customer comments
No comments were found for Nyxoah Announces Submission of Draft Registration Statement for Proposed Public Listing in the United States. Be the first to comment!